The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN).

Condition	Treatment or Intervention	Phase
Preneoplastic Conditions Prostatic Intraepithelial Neoplasia	Drug: toremifene citrate	Phase III

Further Study Details: 

Primary Outcomes: To assess the efficacy of toremifene in the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN)
Secondary Outcomes: To assess the safety of toremifene in men with high grade PIN; To assess the effect of toremifene on lipid levels; To assess the effect of toremifene on hormone levels; To assess the effect of toremifene on total and % free serum PSA (prostate specific antigen) levels; To assess the effect of toremifene on the AUA (American Urological Association) symptom score; To assess the population pharmacokinetics of 20 mg toremifene in men
Expected Total Enrollment:  1260

The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia. Men who have ever been diagnosed with high grade PIN will be enrolled into an 18 month trial and will be assigned to either 20 mg of study drug or placebo per day. Subjects will undergo safety evaluations at Month 3, Month 6, Month 12 and Month 18 along with prostate biopsies at Month 12 and Month 18 to determine efficacy.

Ages Eligible for Study:  30 Years and above,  Genders Eligible for Study:  Male

Criteria

Inclusion Criteria:

• Give voluntary signed informed consent in accordance with institutional policies
• Be male, aged ≥ 30 years
• Have a diagnosis of high grade PIN from any previous prostate biopsy. The diagnosis of high grade PIN must be confirmed by the central pathologist
• Have had a prostate biopsy in the last 6 months with a minimum of 10 cores that shows no evidence of cancer as confirmed by the central pathologist; OR, have had 2 prostate biopsies (each with a minimum of 6 cores) in the 12 months prior to screening with at least one of the biopsies occurring within 6 months prior to the screening visit. Both biopsies should have no evidence of cancer as confirmed by the central pathologist
• Have a serum PSA of ≤ 10 ng/mL
• Agree to provide tablet containers for tablet counts
• Agree to use an effective method of contraception, if the partner is of child-bearing age, while on study
• Have adequate bone marrow, liver and renal function: *White Blood Cell (WBC) Count ≥ 3,000/mm3; *Platelet Count ≥ 100,000/mm3; *Bilirubin ≤ 1.5 mg/dL; *AST and ALT < 2x upper limit of normal; *Serum Creatinine ≤ 2.0 mg%

Exclusion Criteria:

• Previous exposure to toremifene citrate
• Have evidence of prostate cancer (local, regional and/or distal metastasis)
• Have any history of other malignancies (exceptions include non-melanoma skin cancer or other cancer that has no evidence of tumor reoccurrence, 5 years after definitive treatment). Superficial bladder cancer is acceptable as long as it has been greater than 1 year since any treatment with no evidence of recurrence.
• Have active systemic viral, bacterial, or fungal infections requiring treatment
• Have, in the judgment of the investigator, a clinically significant concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol
• Concurrently being treated with other investigational agents or have participated in an investigational study within 30 days prior to screening
• Currently taking dutasteride. Subject is eligible if he stops dutasteride for a total washout of 90 days prior to the Screening Visit and agrees not to use dutasteride for the duration of the study.
• Have previously taken finasteride for greater than two years
• Currently taking finasteride. Subject is eligible if he stops finasteride for a total washout of 30 days prior to the Screening Visit and agrees not to use finasteride for the duration of the study.
• Currently taking testosterone or testosterone-like supplements, such as dehydroepiandrosterone (DHEA). Subject is eligible if he stops these agents for a total washout of 30 days prior to the Screening Visit and agrees not to use these agents for the duration of the study.
• Have a history of taking PC-SPES within the past two years.
• Currently taking herbal medicine or dietary supplements for prostate health, such as Saw Palmetto (also known as Serenoa repens). Subject is eligible if he stops these agents for a total washout of 30 days prior to taking the first dose of study drug and agrees not to use these agents for the duration of the study. Lycopene, vitamin E and selenium are not prohibited and no washout is required. However, vitamin E intake should be limited to less than 400 i.u. per day.
• Have a history of thromboembolic event or disease including deep vein thrombosis, pulmonary embolus, or thrombotic stroke
• History of chronic hepatitis or cirrhosis

Michigan
      Michigan Institute of Urology, St. Clair Shores,  Michigan,  48081,  United States; Recruiting

Study ID Numbers:  G300104
Record last reviewed:  March 2005
Last Updated:  March 30, 2005
Record first received:  March 29, 2005
ClinicalTrials.gov Identifier:  NCT00106691
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08